Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06740383 · ClinicalTrials.gov registry record
Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
A clinical trial of Schizophrenia and Schizoaffective Disorder, sponsored by Beth Israel Deaconess Medical Center.
- Recruiting
- Registry status
- 320
- Enrollment target
- 6
- Study locations
NCT06740383 is a study of Schizophrenia and Schizoaffective Disorder that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 320 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (47% higher). The trial reports 6 study locations across 5 states.
The verdict
NCT06740383, a study of Schizophrenia and Schizoaffective Disorder, is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.
- RECRUITING
- Registry status
- 320 participants
- Enrollment target
- 6
- Study locations
Study Summary
The Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS) study aims to understand the early stages of psychotic disorders like Schizophrenia, Schizoaffective Disorder, and Bipolar I Disorder. It involves gathering mental health information, brain scans (MRI), eye movement patterns (Eye-Tracking), and brain electrical waves (EEG) data from individuals who have experienced these disorders in recent years. Participants will be involved for about a year, with four visits over this period. Screening procedures, lasting approximately 3 hours, include tests for drug use, a pregnancy test for eligible women, clinical interviews about feelings and experiences, psychiatric and family history interviews, and a medical history review. Research procedures for eligible participants include DNA collection, a neuropsychological test battery, EEG, eye-tracking, and MRI. These procedures will help researchers understand brain function, genetics, and cognitive abilities related to psychotic disorders. Follow-up visits at 1-month, 6-month, and 12-month intervals involve modified clinical interviews and repeating neuropsychological tests to track changes over time. Participants may opt to provide DNA samples for genetic analysis, undergo various cognitive tests, EEG to record brain waves, eye-tracking to monitor eye movements, and MRI scans to visualize brain structure. Follow-up visits at regular intervals will help researchers track changes in symptoms and cognitive function. This study provides comprehensive insight into the onset and progression of psychotic disorders and offers valuable information for patients, families, and healthcare providers involved in managing these conditions. Our goal is to better understand whether a combination of biological markers and different types of people (BT1, BT2, BT3) can help us predict how well individuals with early psychosis respond to specialized care. We expect that those in BT3 will have the best outcomes, BT2 w
Conditions Studied
Study Locations (6)
Massachusetts
- McLean Hospital - Belmont
- Beth Israel Deaconess Medical Center - Boston
Connecticut
- Hartford Hospital - Hartford
Georgia
- University of Georgia - Athens
Illinois
- University of Chicago Medical Center - Chicago
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2027-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06740383
The ClinicalTrials.gov registry entry for NCT06740383 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (47% higher). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Schizophrenia appearing as the primary indexed condition, and to 0 interventions.
NCT06740383 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, Connecticut, Georgia.
Frequently Asked Questions
What is clinical trial NCT06740383 about?
NCT06740383 is a clinical study titled "Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services". The Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS) study aims to understand the early stages of psychotic disorders like Schizophrenia, Schizoaffective Disorder, and Bipolar I Disorder. It involves gathering mental health information, brain scans (MRI), eye movement p...
What is the current status of trial NCT06740383?
This trial is currently recruiting. The enrollment target is 320 participants. The study started on 2023-01-01. Estimated completion is 2027-06-30.
What conditions does trial NCT06740383 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder, Early Psychosis, Bipolar 1 Disorder, Schizophrenia Spectrum and Other Psychotic Disorders.
Who is sponsoring clinical trial NCT06740383?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06740383 being conducted?
This trial has 6 study locations across Connecticut, Georgia, Illinois, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Taking Action for College Students
RECRUITING · NA
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.